Porter v. Pfizer, Inc.

Filing 16

MDL CONDITIONAL TRANSFERRING ORDER (CTO-7) TO THE USDC FOR THE DISTRICT OF CAROLINA (MDL 2502). Signed by Jeffrey N. Luthi for the MDL Panel on 3/19/14. (ysS, COURT STAFF) (Filed on 3/19/2014)

2:14-mn-02502-RMG Date Filed 03/19/14 Entry Number 31 Page 1 of 3
Case MDL No. 2502 Document 166 Filed 03/19/14 Page 1 of 3
UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

IN RE: LIPITOR (ATORVASTATIN CALCIUM)
MARKETING, SALES PRACTICES AND
PRODUCTS LIABILITY LITIGATION (NO. II)

MDL No. 2502

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO −7)

On February 18, 2014, the Panel transferred 42 civil action(s) to the United States District Court for
the District of South Carolina for coordinated or consolidated pretrial proceedings pursuant to 28
U.S.C. §1407. See _F.Supp.2d_ (J.P.M.L. 2014). Since that time, 198 additional action(s) have been
transferred to the District of South Carolina. With the consent of that court, all such actions have
been assigned to the Honorable Richard M Gergel.
It appears that the action(s) on this conditional transfer order involve questions of fact that are
common to the actions previously transferred to the District of South Carolina and assigned to Judge
Gergel.
Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict
Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. §1407 to the
District of South Carolina for the reasons stated in the order of February 18, 2014, and, with the
consent of that court, assigned to the Honorable Richard M Gergel.
This order does not become effective until it is filed in the Office of the Clerk of the United States
District Court for the District of South Carolina. The transmittal of this order to said Clerk shall be
stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the
Panel within this 7−day period, the stay will be continued until further order of the Panel.

FOR THE PANEL:
Mar 19, 2014
Jeffery N. Lüthi
Clerk of the Panel

2:14-mn-02502-RMG Date Filed 03/19/14 Entry Number 31 Page 2 of 3
Case MDL No. 2502 Document 166 Filed 03/19/14 Page 2 of 3

IN RE: LIPITOR (ATORVASTATIN CALCIUM)
MARKETING, SALES PRACTICES AND
PRODUCTS LIABILITY LITIGATION (NO. II)

SCHEDULE CTO−7 − TAG−ALONG ACTIONS

DIST

DIV.

C.A.NO.

CASE CAPTION

CALIFORNIA NORTHERN
CAN
CAN

3
3

14−00660
14−00736

Casanas v. Pfizer, Inc.
Porter v. Pfizer, Inc.

3

14−00170

Spivey et al v. Pfizer Inc.

2

14−00067

Wright v. Pfizer Inc.

CONNECTICUT
CT
IDAHO
ID

INDIANA SOUTHERN
INS

1

14−00299

HAMILTON v. PFIZER, INC.

14−00070

Richeson v. Pfizer Inc

IOWA SOUTHERN
IAS

4

KENTUCKY EASTERN
KYE

6

14−00025

Wyrick v. Pfizer Inc.

LOUISIANA MIDDLE
LAM

3

14−00128

Firmin v. Pfizer, Inc.

NORTH CAROLINA EASTERN
NCE

5

14−00024

Bass v. Pfizer Inc.

14−00401

Wallace v. Pfizer, Inc.

OHIO NORTHERN
OHN

1

MDL No. 2502

2:14-mn-02502-RMG Date Filed 03/19/14 Entry Number 31 Page 3 of 3
Case MDL No. 2502 Document 166 Filed 03/19/14 Page 3 of 3
WEST VIRGINIA NORTHERN
WVN

5

14−00029

Stevey v. Pfizer Inc.

WEST VIRGINIA SOUTHERN
WVS
WVS
WVS
WVS
WVS
WVS

2
2
2
2
2
2

14−10766
14−10900
14−10997
14−11054
14−11158
14−11170

Stoneking v. Pfizer, Inc.
Sayre v. Pfizer Inc.
Goodson v. Pfizer Inc.
Good v. Pfizer Inc.
Given v. Pfizer Inc.
Olson v. Pfizer Inc.